Dare Bioscience DARE 深 滬
等待開盤 07-19 09:30:00 美东时间
2.52
+0.020
+0.80%
華盛通- 最 高2.63
- 今 開2.51
- 成交量 59.61万股
- 最 低 2.46
- 昨 收 2.50
- 總市值 2230.30万
- 52周最高 9.19
- 市盈率 靜 --
- 換手率 6.74%
- 52周最低 2.11
- 委 比 -30.27%
- 總股本 885.04万
- 歷史最高 76.44
- 量 比 0.03
- 振 幅 6.80%
- 歷史最低 2.11
- 每 手 1
- 風險率 0.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多3 Penny Stocks to Watch Now, 7/15/25
Dare Bioscience, LQR House, and Canaan Inc. are the 3Penny Stocksto...
07-15 19:04
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Daré Bioscience announced interim positive results from its Phase 3 trial for Ovaprene, a hormone-free, monthly intravaginal contraceptive. With approximately 9% pregnancy rate and favorable safety and tolerability, Ovaprene shows potential as a meaningful alternative to existing contraceptives. No serious safety concerns were reported, though 17% of participants discontinued due to vaginal odor. The study is expected to continue as planned, targ...
07-14 12:00
Daré Bioscience shares are trading higher after the company received a $6 million non-dilutive grant installment under its agreement to support DARE-LARC1.
Daré Bioscience shares are trading higher after the company received a $6 milli...
07-11 20:02
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
Daré Bioscience, a biopharmaceutical company, has received a $6 million non-dilutive funding installment to support the development of DARE-LARC1, a long-acting reversible contraceptive (LARC) utilizing its intelligent drug delivery system (DARE-IDDS) platform. This brings the total funding to approximately $37.8 million. DARE-IDDS, originally developed at MIT, is a programmable, wirelessly controlled device capable of delivering up to hundreds o...
07-11 12:00
抽象自由的代价：奥地利学派如何为种族主义铺路
Quinn Slobodian, Hayek’s Bastards: Race, Gold, IQ, and the Capitalism of the Fa...
06-24 11:18
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
Daré Bioscience, Inc. announced that its 2025 annual stockholder meeting was adjourned due to lack of a quorum. The meeting will reconvene on July 9, 2025, at 9:00 a.m. PT, held virtually. Stockholders as of April 17, 2025, who have not voted are encouraged to vote online at www.proxyvote.com or by phone by July 8, 2025.
06-12 21:00
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
Daré Bioscience and Rosy Wellness announce a strategic collaboration to launch Daré’s DARE to PLAY Sildenafil Cream, a topical treatment for female sexual arousal disorder. The partnership combines Daré’s clinical expertise with Rosy’s community of over 250,000 women to raise awareness and reduce stigma around female sexual health. The product, using sildenafil citrate like Viagra, aims to improve genital blood flow and is expected to be availabl...
06-04 12:00
Personalis Presents New Clinical Results From PREDICT DNA And SCANDARE Studies Highlighting Capabilities Of Ultrasensitive NeXT Personal ctDNA Blood Test For Monitoring And Predicting NAT Response In TNBC
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its
06-03 04:02
Natera To Present Data From 25 Signatera Studies Covering Nearly 25,000 Patients Across 10 Cancer Types At ASCO 2025, Highlighting MRD Detection, Treatment Monitoring, And Pan-Cancer Utility Including Breast, GI, GU, Skin, And Sarcoma Trials
Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of SignateraBreast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized
05-23 05:32
